Priyanka Vyas, MD
Pulmonary Disease · Montgomery, ALNPI 1609023993
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,057 of the $11,612 with a category attached, or 60.8%. Intuitive Surgical accounts for 63.0% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $7,697, more than ten times the $769 reported in 2019.
Across 247 payments — averaging $47.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- GSK$1K
- Insmed, Inc.$569
- AstraZeneca$407
- Boehringer Ingelheim$370
- Regeneron Healthcare Solutions, Inc.$214
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2012%
- Food & beverage$4,35538%
- Education$7,05761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $7,318 |
| GSK | 86 | $1,349 |
| Insmed, Inc. | 23 | $569 |
| AstraZeneca(2 entities) | 24 | $407 |
| Boehringer Ingelheim | 19 | $370 |
| Regeneron Healthcare Solutions, Inc. | 10 | $214 |
| Philips North America LLC | 9 | $171 |
| Mylan Specialty L.p. | 11 | $170 |
| Gilead | 8 | $154 |
| Genentech USA, Inc. | 9 | $142 |
| Grifols USA, LLC | 6 | $112 |
| Jazz Pharmaceuticals Inc. | 4 | $103 |
| Amgen | 3 | $66 |
| AbbVie(2 entities) | 3 | $66 |
| Paratek Pharmaceuticals, Inc. | 3 | $55 |
| Electromed, Inc. | 5 | $52 |
| Inspire Medical Systems, Inc. | 1 | $43 |
| Merck | 2 | $40 |
| United Therapeutics Corporation | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $40 |
| Olympus America Inc. | 1 | $28 |
| Ambu Inc. | 1 | $25 |
| Inogen, Inc. | 1 | $24 |
| Circassia Inc. | 1 | $20 |
| Sanofi | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,165
- TRELEGY ELLIPTA$119
How this compares
$11,612 in reported general payments places this provider in the 80th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $476,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 529 | $400,227 |
| Breo ElliptaFluticasone/Vilanterol | 212 | $104,667 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 129 | $70,295 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $34,074 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $17,693 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 102 | $13,369 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 518 | $11,193 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $10,706 |
| Pirfenidone | 13 | $10,416 |
| Wixela InhubFluticasone Propion/Salmeterol | 82 | $8,668 |
| Arnuity ElliptaFluticasone Furoate | 28 | $6,245 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $4,468 |
| Roflumilast | 45 | $3,697 |
| Montelukast Sodium | 271 | $2,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,349 | $581,434898 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $370 | $487,33044 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $407 | $51,768112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Montgomery
- William SaliskiMontgomery$257K
- Apurva BansalMontgomery$15K
- Walter GribbenMontgomery$13K
- Adrian Noriega AldaveMontgomery$11K
- Lisa WilliamsMontgomery$9K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
- Luther CorleyHuntsville$86K
- Peter LutzMobile$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.